BRCA2 and neoplasm: The sensitivity of BRCA2-deficient tumours to inhibitors of the DNA repair enzyme PARP has been exploited therapeutically18, emphasising the importance of elucidating the mechanisms of such synthetic lethality and the ensuing resistance following treatment.